Advancing a Candidate Polyclonal Antibody Therapy for Hantavirus Disease

推进汉坦病毒病候选多克隆抗体疗法

• 批准号: 9976978
• 负责人: Jay Williams Hooper
• 金额: $ 104.98万
• 依托单位: GENEVA FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-18 至 2022-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9976978
• 关键词: Age; Andes Virus; Animal Model; Animal Sources; Antibodies; Antibody Therapy; Biological Assay; Biological Response Modifier Therapy; Case Fatality Rates; Categories; Cattle; Cell Culture Techniques; Chile; Chromosomes, Artificial, Human; Clinical; Communicable Diseases; Cyclic GMP; DNA Vaccines; Dangerousness; Devices; Disease; Disease Progression; Drug Kinetics; Endemic Diseases; Engineering; Etiology; FDA approved; Genes; Goals; Hamsters; Hantaan virus; Hantavirus; Hantavirus Pulmonary Syndrome; Hemorrhagic Fever with Renal Syndrome; Human; Immunize; Immunoglobulins; Immunotherapeutic agent; In Vitro; Infection; Intensive Care Units; Jet Injections; Knock-out; Light; Measures; Medical Research; Mesocricetus auratus; Modeling; Modernization; Morbidity - disease rate; National Institute of Allergy and Infectious Disease; Needles; New Mexico; Oryctolagus cuniculus; Pathogenicity; Patients; Persons; Pharmaceutical Preparations; Phase; Phase I Clinical Trials; Plasma; Preclinical Testing; Prevention; Procedures; Prophylactic treatment; Puumala virus; Reporting; Research; Research Institute; Respiratory distress; Shock; Sin Nombre virus; Standardization; Survivors; Sweden; Symptoms; Technology; Testing; Therapeutic; Toxicity Tests; Vaccinated; Virus; Virus Diseases; Zoonoses; base; cross reactivity; efficacy study; human tissue; hyperimmunization; in vitro activity; in vivo; lead candidate; medical countermeasure; neutralizing antibody; nonhuman primate; novel; polyclonal antibody; preclinical safety; preclinical toxicity; prevent; priority pathogen; prophylactic; protective efficacy; research and development; research clinical testing; safety testing; stability testing; transmission process

PROJECT SUMMARY/ABSTRACT Hantaviruses are the etiological agents of hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS). There are no FDA-approved medical countermeasures to prevent or treat these unpredictable zoonotic diseases. Recently, clinicians in Chile demonstrated that convalescent plasma from HPS survivors provided a clinical benefit in HPS patients in a compassionate-use study. However, the paucity of available human plasma containing high-titer neutralizing antibodies against hantaviruses, and other drawbacks to the use of human plasma derived products, makes the use of convalescent plasma as an anti- hantavirus product untenable. We propose to further develop a potent polyclonal antibody anti-hantavirus product using transchromosomal (Tc) bovine technology. This technology overcomes the significant challenges presented by therapies consisting of polyclonal antibodies obtained from human plasma donors or animal sources. SAB’s diversitAb™ platform technology uses cattle carrying knockouts of key bovine antibody heavy light chains genes, and the addition of a Human Artificial Chromosome containing the entire human heavy chain locus and the entire human kappa light chain locus. As partners, SAB and the US Army Medical Research Institute of Infectious Diseases (USAMRIID) have already demonstrated that fully-human IgG purified from plasma collected from the Tc bovines immunized with hantavirus DNA vaccines has potent neutralizing antibody activity in vitro, and is protective in vivo (i.e., Syrian hamster models of lethal HPS disease). Here, we will use our existing hantavirus DNA vaccines and diversitAb™ platform technology to produce a pan-hantavirus polyclonal antibody product under cGMP. We will conduct in vitro neutralization assays to measure potency, and in vivo efficacy studies using established Syrian hamster models of infection and disease. In addition, we will subject the candidate product to stability testing, human tissue cross reactivity testing, pharmacokinetic analysis in nonhuman primates, and a GLP preclinical toxicity study in rabbits. Our goal is to advance a lead candidate anti-hantavirus polyclonal antibody immunotherapeutic product through preclinical testing. At the conclusion of these IND-enabling studies, this candidate anti-hantavirus product will be ready for a Phase 1 clinical trial.

项目摘要/摘要 汉坦病毒是汉坦病毒肺综合征(HPS)和出血热的病原体。 肾综合征(HFRS)。没有FDA批准的医学对策来预防或治疗这些疾病 不可预测的人畜共患病。最近，智利的临床医生证明，恢复期的血浆 在一项同情使用研究中，HPS幸存者为HPS患者提供了临床益处。然而，稀缺 含有针对汉坦病毒的高效价中和抗体的可用人类血浆，以及其他 使用人类血浆衍生产品的缺点，使得使用恢复期的血浆作为抗 汉坦病毒产品站不住脚。我们建议进一步开发一种有效的抗汉坦病毒的多克隆抗体。 产品使用跨染色体(TC)牛技术。这项技术克服了重大挑战 由从人类血浆捐献者或动物获得的多克隆抗体组成的疗法呈现 消息来源。SAB的DiversitAb™平台技术使用牛携带关键牛抗体重链的敲除 轻链基因，以及添加包含整个人类重链的人类人工染色体 以及整个人类kappa轻链基因。作为合作伙伴，SAB和美国陆军医疗 传染病研究所(USAMRIID)已经证明了完全人类免疫球蛋白 从汉坦病毒DNA疫苗免疫的TC牛采集的血浆中纯化出有效的 体外中和抗体活性，在体内具有保护性(即致死性HPS叙利亚仓鼠模型 疾病)。在这里，我们将使用我们现有的汉坦病毒DNA疫苗和多元化抗体™平台技术来 制备cGMP下泛汉坦病毒多克隆抗体产品。我们将进行体外中和 利用已建立的叙利亚仓鼠感染模型进行效力测定和体内疗效研究 和疾病。此外，我们将对候选产品进行稳定性测试，人体组织交叉反应 测试，在非人类灵长类动物中的药代动力学分析，以及在兔身上的GLP临床前毒性研究。我们的 目标是通过以下途径开发一种主要的候选抗汉坦病毒多克隆抗体免疫治疗产品 临床前测试。在这些启用IND的研究结束时，这种候选的抗汉坦病毒产品将 为一期临床试验做好准备。